Ligand Pharmaceuticals (LGND) Tops Q4 EPS by 3c on Strong Revenues; Guides for 2010
Tweet Send to a Friend
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reports Q4 EPS of $0.01, 3 cents better than estimates. Revenues were $13.98 million ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
